WO2011153416A3 - Variants d'anticorps anti-s1p inédits de lt1009 - Google Patents

Variants d'anticorps anti-s1p inédits de lt1009 Download PDF

Info

Publication number
WO2011153416A3
WO2011153416A3 PCT/US2011/039039 US2011039039W WO2011153416A3 WO 2011153416 A3 WO2011153416 A3 WO 2011153416A3 US 2011039039 W US2011039039 W US 2011039039W WO 2011153416 A3 WO2011153416 A3 WO 2011153416A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
antibody variants
novel anti
antibody
silico
Prior art date
Application number
PCT/US2011/039039
Other languages
English (en)
Other versions
WO2011153416A2 (fr
Inventor
Jonathan Michael Wojciak
Original Assignee
Lpath, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lpath, Inc. filed Critical Lpath, Inc.
Publication of WO2011153416A2 publication Critical patent/WO2011153416A2/fr
Publication of WO2011153416A3 publication Critical patent/WO2011153416A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Evolutionary Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Medical Informatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des procédés de conception d'anticorps optimisés ciblant des lipides bioactifs. Ces procédés peuvent être mis en œuvre in silico et peuvent avoir pour but de renforcer l'affinité de liaison d'un anticorps avec son lipide cible initial et/ou de modifier ladite affinité de liaison. L'invention concerne également des variants d'anticorps inédits obtenus par ces procédés, ainsi que leurs procédés de fabrication et d'utilisation.
PCT/US2011/039039 2010-06-04 2011-06-03 Variants d'anticorps anti-s1p inédits de lt1009 WO2011153416A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35182610P 2010-06-04 2010-06-04
US61/351,826 2010-06-04

Publications (2)

Publication Number Publication Date
WO2011153416A2 WO2011153416A2 (fr) 2011-12-08
WO2011153416A3 true WO2011153416A3 (fr) 2013-04-11

Family

ID=45067309

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/039039 WO2011153416A2 (fr) 2010-06-04 2011-06-03 Variants d'anticorps anti-s1p inédits de lt1009

Country Status (1)

Country Link
WO (1) WO2011153416A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100098700A1 (en) * 2008-04-05 2010-04-22 Sabbadini Roger A Pharmaceutical compositions for binding sphingosine-1-phosphate
WO2010065921A2 (fr) * 2008-12-05 2010-06-10 Lpath, Inc. Conception d'anticorps à l'aide de structures cristallines d'anticorps anti-lipidiques

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100098700A1 (en) * 2008-04-05 2010-04-22 Sabbadini Roger A Pharmaceutical compositions for binding sphingosine-1-phosphate
WO2010065921A2 (fr) * 2008-12-05 2010-06-10 Lpath, Inc. Conception d'anticorps à l'aide de structures cristallines d'anticorps anti-lipidiques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
0' BRIEN, N. ET AL.: "Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies", JOURNAL OF LIPID RESEARCH, vol. 50, 9 June 2009 (2009-06-09), pages 2245 - 2257, XP055164819, DOI: doi:10.1194/jlr.M900048-JLR200 *
WOJCIAK, J. M. ET AL.: "The crystal structure of sphingosine-1-phosphate in complex with a Fab fragment reveals metal bridging of an antibody and its antigen", PROC. NATL. ACAD. SCI. USA, vol. 106, no. 42, 7 October 2009 (2009-10-07), pages 17717 - 17722, XP008149606, DOI: doi:10.1073/pnas.0906153106 *

Also Published As

Publication number Publication date
WO2011153416A2 (fr) 2011-12-08

Similar Documents

Publication Publication Date Title
WO2013173761A3 (fr) Protéines de liaison à l'antigène st2
WO2013043933A3 (fr) Protéines de liaison à un antigène cd27l
WO2011047146A3 (fr) Procédés de maturation d'affinité d'anticorps
WO2011130377A3 (fr) Protéines de liaison à la bêta amyloïde
AU2009260320A8 (en) Antibodies to IL-6 and their uses
WO2013096380A3 (fr) Anticorps anti-phf-tau et leurs utilisations
WO2011113019A3 (fr) Protéines ctla4 et leurs utilisations
WO2013188693A8 (fr) Constructions de liaison à l'antigène pour cd3
WO2013063613A3 (fr) Procédés et compositions associés à la neutralisation intracellulaire par une igg
WO2012162067A3 (fr) Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines
IN2012DN03911A (fr)
WO2013064701A3 (fr) Anticorps bispécifiques et méthodes d'isolement de ceux-ci
WO2012064792A3 (fr) Complexes protéiques pour la liaison à un antigène, et leurs procédés d'utilisation
WO2013021279A3 (fr) Anticorps fortement galactosylés
WO2012064836A9 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
WO2012031099A3 (fr) Anticorps anti-cxcl13 et leurs procédés d'utilisation
WO2012009544A3 (fr) Immunoglobuline à insertion de domaine
WO2011130603A3 (fr) Anticorps anti-vla-4
WO2012125733A3 (fr) Méthodes de dépistage d'anticorps
WO2009130459A3 (fr) Épitopes d’il-17a et d’il-17f, et anticorps spécifiques à ceux-ci
WO2011109726A3 (fr) Anticorps homologues multispécifiques
WO2011092593A3 (fr) Anticorps neutralisant le vih-1 et leurs utilisations
WO2010136483A3 (fr) Protéines de liaison à l'antigène
WO2012010978A3 (fr) Procédé de traitement de la maladie d'alzheimer
WO2013093627A3 (fr) Maturation d'affinité in silico

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC DATED 19.03.13

122 Ep: pct application non-entry in european phase

Ref document number: 11790452

Country of ref document: EP

Kind code of ref document: A2